Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and...
share announcement

Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 21448

Special Issue Editors

Prof. Dr. Ornella Parolini

E-Mail Website
Guest Editor
Faculty of Medicine and Surgery “A. Gemelli”, Università Cattolica del Sacro Cuore, Via della Pineta Sacchetti, 217, 00168 Rome , Italy
Interests: regenerative medicine; immunomodulation of mesenchymal stromal cells and secretome from human term placenta at the basis for tissue regeneration
Dr. Antonietta Rosa Silini

E-Mail Website
Guest Editor
Centro di Ricerca E. Menni, Fondazione Poliambulanza Istituto Ospedaliero, 25124 Brescia, Italy
Interests: regenerative medicine; placenta; amniotic membrane; mesenchymal stromal cells; secretome; immunomodulation
Special Issues, Collections and Topics in MDPI journals
Dr. Francesca Romana Stefani

E-Mail Website
Guest Editor
Centro di Ricerca E. Menni, Fondazione Poliambulanza Istituto Ospedaliero, 25124 Brescia, Italy
Interests: Tumor Microenvironment and its Contribution to Cancer Progression; Novel Therapeutic Approaches for Cancer Treatment; Biology of Human Placenta and its Derivatives and their Potential Restorative Ability in Inflammation-Associated Disorders

Special Issue Information

Dear Colleagues,

As of today, the controversy about the role for mesenchymal stromal cells (MSC) in both progression and regression of cancer has yet to be unraveled. MSC have been widely explored as therapeutic tool in regenerative medicine, nevertheless their actual role within the tissue of origin as well as in cancer development and progression still represents an open question. Specifically, how MSC and tumor/tumor-associated cells shape each other’s phenotype and therefore influence disease progression represents an area of intense investigation. Thanks to the effort of many, the phenotype of MSC from various sources is shaping up, although a clear identity and immunological make up has yet to be fully defined. Besides, implementation of MSC biology as a therapeutic tool for cancer adds further complexity to the topic. Many factors may influence the therapeutic outcome of MSC in cancer, including temporal and spatial distribution of the cells within or outside the tumor tissue, stage of the disease and type of immune response.

For this Special Issue, we invite renowned scientists to contribute with original articles as well as review articles to the understanding of the complex biology of MSC in health and disease and how this could be exploited for therapeutic purposes in cancer.

Potential topics include, but are not limited to:

- The role of endogenous MSC in cancer development and progression.

- The crosstalk between MSC and the different components of the tumor and its microenvironment.

- New technologies for tracking the path of endogenous MSC over the course of the disease.

- The use of exogenously administered MSC in the treatment of cancer.

Prof. Dr. Ornella Parolini
Dr. Antonietta Rosa Silini
Dr. Francesca Romana Stefani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Mesenchymal Stromal Cells
  • Cancer Treatment
  • Tumor Microenvironment

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 196 KiB  
Editorial
Mesenchymal Stromal Cells: From Therapeutic Option to Therapeutic Target
by Francesca Romana Stefani, Ornella Parolini and Antonietta Rosa Silini
Cancers 2023, 15(6), 1873; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15061873 - 21 Mar 2023
Viewed by 829
Abstract
As our understanding of mesenchymal stromal cells (MSC) has evolved, they have come to be recognized as an integral part of the tumor tissue, and the exploitability of their intrinsic features in the field of oncology has reached a standstill [...] Full article
(This article belongs to the Special Issue Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy)

Research

Jump to: Editorial, Review

22 pages, 5022 KiB  
Article
Mesenchymal-Stromal Cell-like Melanoma-Associated Fibroblasts Increase IL-10 Production by Macrophages in a Cyclooxygenase/Indoleamine 2,3-Dioxygenase-Dependent Manner
by Uğur Çakır, Anna Hajdara, Balázs Széky, Balázs Mayer, Sarolta Kárpáti, Éva Mezey, Pálma Silló, Gergely Szakács, András Füredi, Zoltán Pós, Barbara Érsek, Miklós Sárdy and Krisztián Németh
Cancers 2021, 13(24), 6173; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13246173 - 07 Dec 2021
Cited by 6 | Viewed by 3146
Abstract
Melanoma-associated fibroblasts (MAFs) are integral parts of melanoma, providing a protective network for melanoma cells. The phenotypical and functional similarities between MAFs and mesenchymal stromal cells (MSCs) prompted us to investigate if, similarly to MSCs, MAFs are capable of modulating macrophage functions. Using [...] Read more.
Melanoma-associated fibroblasts (MAFs) are integral parts of melanoma, providing a protective network for melanoma cells. The phenotypical and functional similarities between MAFs and mesenchymal stromal cells (MSCs) prompted us to investigate if, similarly to MSCs, MAFs are capable of modulating macrophage functions. Using immunohistochemistry, we showed that MAFs and macrophages are in intimate contact within the tumor stroma. We then demonstrated that MAFs indeed are potent inducers of IL-10 production in various macrophage types in vitro, and this process is greatly augmented by the presence of treatment-naïve and chemotherapy-treated melanoma cells. MAFs derived from thick melanomas appear to be more immunosuppressive than those cultured from thin melanomas. The IL-10 increasing effect is mediated, at least in part, by cyclooxygenase and indoleamine 2,3-dioxygenase. Our data indicate that MAF-induced IL-10 production in macrophages may contribute to melanoma aggressiveness, and targeting the cyclooxygenase and indoleamine 2,3-dioxygenase pathways may abolish MAF–macrophage interactions. Full article
(This article belongs to the Special Issue Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy)
►▼ Show Figures

Figure 1

26 pages, 4248 KiB  
Article
The Constitutive Extracellular Protein Release by Acute Myeloid Leukemia Cells—A Proteomic Study of Patient Heterogeneity and Its Modulation by Mesenchymal Stromal Cells
by Elise Aasebø, Annette K. Brenner, Even Birkeland, Tor Henrik Anderson Tvedt, Frode Selheim, Frode S. Berven and Øystein Bruserud
Cancers 2021, 13(7), 1509; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13071509 - 25 Mar 2021
Cited by 10 | Viewed by 3680
Abstract
Extracellular protein release is important both for the formation of extracellular matrix and for communication between cells. We investigated the extracellular protein release by in vitro cultured normal mesenchymal stem cells (MSCs) and by primary human acute myeloid leukemia (AML) cells derived from [...] Read more.
Extracellular protein release is important both for the formation of extracellular matrix and for communication between cells. We investigated the extracellular protein release by in vitro cultured normal mesenchymal stem cells (MSCs) and by primary human acute myeloid leukemia (AML) cells derived from 40 consecutive patients. We observed quantifiable levels of 3082 proteins in our study; for the MSCs, we detected 1446 proteins, whereas the number of released proteins for the AML cells showed wide variation between patients (average number 1699, range 557–2380). The proteins were derived from various cellular compartments (e.g., cell membrane, nucleus, and cytoplasms), several organelles (e.g., cytoskeleton, endoplasmatic reticulum, Golgi apparatus, and mitochondria) and had various functions (e.g., extracellular matrix and exosomal proteins, cytokines, soluble adhesion molecules, protein synthesis, post-transcriptional modulation, RNA binding, and ribonuclear proteins). Thus, AML patients were very heterogeneous both regarding the number of proteins and the nature of their extracellularly released proteins. The protein release profiles of MSCs and primary AML cells show a considerable overlap, but a minority of the proteins are released only or mainly by the MSC, including several extracellular matrix molecules. Taken together, our observations suggest that the protein profile of the extracellular bone marrow microenvironment differs between AML patients, these differences are mainly caused by the protein release by the leukemic cells but this leukemia-associated heterogeneity of the overall extracellular protein profile is modulated by the constitutive protein release by normal MSCs. Full article
(This article belongs to the Special Issue Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

35 pages, 937 KiB  
Review
Mesenchymal Stem/Stromal Cells May Decrease Success of Cancer Treatment by Inducing Resistance to Chemotherapy in Cancer Cells
by Taja Železnik Ramuta and Mateja Erdani Kreft
Cancers 2022, 14(15), 3761; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14153761 - 02 Aug 2022
Cited by 5 | Viewed by 2055
Abstract
The tumour microenvironment, which is comprised of various cell types and the extracellular matrix, substantially impacts tumour initiation, progression, and metastasis. Mesenchymal stem/stromal cells (MSCs) are one of the key stromal cells in the tumour microenvironment, and their interaction with cancer cells results [...] Read more.
The tumour microenvironment, which is comprised of various cell types and the extracellular matrix, substantially impacts tumour initiation, progression, and metastasis. Mesenchymal stem/stromal cells (MSCs) are one of the key stromal cells in the tumour microenvironment, and their interaction with cancer cells results in the transformation of naïve MSCs to tumour-associated MSCs. The latter has an important impact on tumour growth and progression. Recently, it has been shown that they can also contribute to the development of chemoresistance in cancer cells. This review provides an overview of 42 studies published between 1 January 2001 and 1 January 2022 that examined the effect of MSCs on the susceptibility of cancer cells to chemotherapeutics. The studies showed that MSCs affect various signalling pathways in cancer cells, leading to protection against chemotherapy-induced damage. Promising results emerged from the use of inhibitors of various signalling pathways that are affected in cancer cells due to interactions with MSCs in the tumour microenvironment. These studies present a good starting point for the investigation of novel treatment approaches and demonstrate the importance of targeting the stroma in the tumour microenvironment to improve treatment outcomes. Full article
(This article belongs to the Special Issue Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy)
►▼ Show Figures

Figure 1

18 pages, 1251 KiB  
Review
Fight the Cancer, Hit the CAF!
by Andrea Papait, Jacopo Romoli, Francesca Romana Stefani, Paola Chiodelli, Maria Cristina Montresor, Lorenzo Agoni, Antonietta Rosa Silini and Ornella Parolini
Cancers 2022, 14(15), 3570; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14153570 - 22 Jul 2022
Cited by 14 | Viewed by 4278
Abstract
The tumor microenvironment (TME) is comprised of different cellular components, such as immune and stromal cells, which co-operate in unison to promote tumor progression and metastasis. In the last decade, there has been an increasing focus on one specific component of the TME, [...] Read more.
The tumor microenvironment (TME) is comprised of different cellular components, such as immune and stromal cells, which co-operate in unison to promote tumor progression and metastasis. In the last decade, there has been an increasing focus on one specific component of the TME, the stromal component, often referred to as Cancer-Associated Fibroblasts (CAF). CAF modulate the immune response and alter the composition of the extracellular matrix with a decisive impact on the response to immunotherapies and conventional chemotherapy. The most recent publications based on single-cell analysis have underlined CAF heterogeneity and the unique plasticity that strongly impact the TME. In this review, we focus not only on the characterization of CAF based on the most recent findings, but also on their impact on the immune system. We also discuss clinical trials and preclinical studies where targeting CAF revealed controversial results. Therefore, future efforts should focus on understanding the functional properties of individual subtypes of CAF, taking into consideration the peculiarities of each pathological context. Full article
(This article belongs to the Special Issue Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy)
►▼ Show Figures

Figure 1

23 pages, 605 KiB  
Review
Mesenchymal Stromal Cells (MSCs): An Ally of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells in Disease Maintenance and Progression within the Bone Marrow Hematopoietic Niche
by Alessandra Fallati, Noemi Di Marzo, Giovanna D’Amico and Erica Dander
Cancers 2022, 14(14), 3303; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14143303 - 06 Jul 2022
Cited by 12 | Viewed by 2690
Abstract
Mesenchymal stromal cells (MSCs) are structural components of the bone marrow (BM) niche, where they functionally interact with hematopoietic stem cells and more differentiated progenitors, contributing to hematopoiesis regulation. A growing body of evidence is nowadays pointing to a further crucial contribution of [...] Read more.
Mesenchymal stromal cells (MSCs) are structural components of the bone marrow (BM) niche, where they functionally interact with hematopoietic stem cells and more differentiated progenitors, contributing to hematopoiesis regulation. A growing body of evidence is nowadays pointing to a further crucial contribution of MSCs to malignant hematopoiesis. In the context of B-cell acute lymphoblastic leukemia (B-ALL), MSCs can play a pivotal role in the definition of a leukemia-supportive microenvironment, impacting on disease pathogenesis at different steps including onset, maintenance and progression. B-ALL cells hijack the BM microenvironment, including MSCs residing in the BM niche, which in turn shelter leukemic cells and protect them from chemotherapeutic agents through different mechanisms. Evidence is now arising that altered MSCs can become precious allies to leukemic cells by providing nutrients, cytokines, pro-survivals signals and exchanging organelles, as hereafter reviewed. The study of the mechanisms exploited by MSCs to nurture and protect B-ALL blasts can be instrumental in finding new druggable candidates to target the leukemic BM microenvironment. Some of these microenvironment-targeting strategies are already in preclinical or clinical experimentation, and if coupled with leukemia-directed therapies, could represent a valuable option to improve the prognosis of relapsed/refractory patients, whose management represents an unmet medical need. Full article
(This article belongs to the Special Issue Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy)
►▼ Show Figures

Figure 1

16 pages, 820 KiB  
Review
Lung-Resident Mesenchymal Stem Cell Fates within Lung Cancer
by Hanna Sentek and Diana Klein
Cancers 2021, 13(18), 4637; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13184637 - 16 Sep 2021
Cited by 5 | Viewed by 3307
Abstract
Lung-resident mesenchymal stem cells (LR-MSCs) are non-hematopoietic multipotent stromal cells that predominately reside adventitial within lung blood vessels. Based on their self-renewal and differentiation properties, LR-MSCs turned out to be important regulators of normal lung homeostasis. LR-MSCs exert beneficial effects mainly by local [...] Read more.
Lung-resident mesenchymal stem cells (LR-MSCs) are non-hematopoietic multipotent stromal cells that predominately reside adventitial within lung blood vessels. Based on their self-renewal and differentiation properties, LR-MSCs turned out to be important regulators of normal lung homeostasis. LR-MSCs exert beneficial effects mainly by local secretion of various growth factors and cytokines that in turn foster pulmonary regeneration including suppression of inflammation. At the same time, MSCs derived from various tissues of origins represent the first choice of cells for cell-based therapeutic applications in clinical medicine. Particularly for various acute as well as chronic lung diseases, the therapeutic applications of exogenous MSCs were shown to mediate beneficial effects, hereby improving lung function and survival. In contrast, endogenous MSCs of normal lungs seem not to be sufficient for lung tissue protection or repair following a pathological trigger; LR-MSCs could even contribute to initiation and/or progression of lung diseases, particularly lung cancer because of their inherent tropism to migrate towards primary tumors and metastatic sites. However, the role of endogenous LR-MSCs to be multipotent tumor-associated (stromal) precursors remains to be unraveled. Here, we summarize the recent knowledge how ‘cancer-educated’ LR-MSCs impact on lung cancer with a focus on mesenchymal stem cell fates. Full article
(This article belongs to the Special Issue Role of Mesenchymal Stromal Cells (MSC) in Cancer Progression and Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop